Search Filters

  • Media Source
  • Presentation Format
  • Media Type
  • Media Year
  • Language
  • Diagnosis / Condition
  • Diagnosis Method
  • Patient Populations
  • Treatment / Technique

Plasma Rich in Growth Factors (PRGF-Endoret) in the Treatment of Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial


Jorge Guadilla, MD
SPAIN

myRating

Plasma Rich in Growth Factors (PRGF-Endoret) in the Treatment of Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial

Mikel Sanchez Alvarez, MD, SPAIN Eduardo Anitua, MD, PhD, SPAIN Jorge Guadilla, MD, SPAIN Juan Azofra, MD, SPAIN Nicolas Fiz, MD, SPAIN Beatriz Aizpurua, MD, SPAIN Tomokazu Yoshioka, MD, PhD, JAPAN Jaime Usabiaga, MD, SPAIN Javier Albillos, MD, SPAIN R. Garate, MD, SPAIN Jose Javier Aguirre, MD, PhD, SPAIN Gorka Orive, PhD, SPAIN

USP Clinica La Esperanza, Vitoria-Gasteiz, Alava, SPAIN

2013 Congress   Paper Abstract   2013 Congress   rating (1)

 

Anatomic Location

Knee

Anatomic Structure

Cartilage

Diagnosis / Condition

Osteoarthritis

Treatment / Technique

Biologics

Summary: This multicenter, double-blind, hyaluronic acid-controlled clinical trial evaluated the efficacy and safety of PRGF-Endoret, an autologous biological therapy for regenerative purposes, as a treatment for knee pain from osteoarthritis.

Background

This multicenter, double-blind, hyaluronic acid-controlled clinical trial evaluated the efficacy and safety of PRGF-Endoret, an autologous biological therapy for regenerative purposes, as a treatment for knee pain from osteoarthritis.

Methods

We randomly assigned 176 patients with symptomatic knee osteoarthritis to receive infiltrations with PRGF-Endoret or with hyaluronic acid (three injections on a weekly basis). The primary outcome measure was a 50 percent decrease in knee pain from baseline to week 24. We also assessed pain, stiffness, and physical function using the WOMAC Index; the rate of response using the criteria of the OMERACT-OARSI; and safety.

Results

The mean age of the patients was 59.8 years, and 52 percent were women. As compared with the rate of response to hyaluronic acid, the rate of response to PRGF-Endoret was 14.1 percentage points higher (P=0.044). Regarding the secondary outcome measures, the rate of response to PRGF-Endoret was in all the cases higher, although no significant differences were reached. For patients with moderate to severe pain at baseline, the rate of response to PRGF-Endoret was 26 percentage points higher (P=0.086) than the rate of response to hyaluronic acid, although no significant differences were reached. Adverse events were mild and evenly distributed among the groups.

Conclusions

PRGF-Endoret has both a faster time to response and more enduring beneficial effect than hyaluronic acid. Treatment with PRGF-Endoret resulted in clinically significant reductions in knee pain, stiffness and physical function, with mild adverse effects, in patients with knee osteoarthritis. (Funded by BTI Biotechnology Institute; ClinicalTrials.gov number, NCT00782197).